News >

AR Emerges as a Potential Target in Triple-Negative Breast Cancer

Allie Strickler @Alliejayes
Published: Friday, Mar 24, 2017

Michael F. Press, MD, PhD

Michael F. Press, MD, PhD

Whereas the androgen receptor (AR) is a common target in the treatment of prostate cancer, Michael F. Press, MD, PhD, shed light on the role of the receptor in breast cancer in a presentation during the 2017 Miami Breast Cancer Conference.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x